228 related articles for article (PubMed ID: 27458215)
1. Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis.
Srivastava S; Modongo C; Siyambalapitiyage Dona CW; Pasipanodya JG; Deshpande D; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5922-7. PubMed ID: 27458215
[TBL] [Abstract][Full Text] [Related]
2. Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.
Sturkenboom MGG; Simbar N; Akkerman OW; Ghimire S; Bolhuis MS; Alffenaar JC
Clin Infect Dis; 2018 Nov; 67(suppl_3):S303-S307. PubMed ID: 30496466
[TBL] [Abstract][Full Text] [Related]
3. Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients.
Modongo C; Pasipanodya JG; Magazi BT; Srivastava S; Zetola NM; Williams SM; Sirugo G; Gumbo T
Antimicrob Agents Chemother; 2016 Oct; 60(10):5928-32. PubMed ID: 27458224
[TBL] [Abstract][Full Text] [Related]
4. Once-a-week tigecycline for the treatment of drug-resistant TB.
Deshpande D; Magombedze G; Srivastava S; Bendet P; Lee PS; Cirrincione KN; Martin KR; Dheda K; Gumbo T
J Antimicrob Chemother; 2019 Jun; 74(6):1607-1617. PubMed ID: 30820554
[TBL] [Abstract][Full Text] [Related]
5. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
[TBL] [Abstract][Full Text] [Related]
6. Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant
Singh S; Gumbo T; Boorgula GD; Thomas TA; Philley JV; Srivastava S
Antimicrob Agents Chemother; 2024 Feb; 68(2):e0108023. PubMed ID: 38131673
[TBL] [Abstract][Full Text] [Related]
7. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.
van Altena R; Dijkstra JA; van der Meer ME; Borjas Howard JF; Kosterink JG; van Soolingen D; van der Werf TS; Alffenaar JW
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069654
[TBL] [Abstract][Full Text] [Related]
8. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
[TBL] [Abstract][Full Text] [Related]
9. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
[TBL] [Abstract][Full Text] [Related]
10. Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.
Musuka S; Srivastava S; Siyambalapitiyage Dona CW; Meek C; Leff R; Pasipanodya J; Gumbo T
Antimicrob Agents Chemother; 2013 Dec; 57(12):5870-7. PubMed ID: 24041886
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis.
Deshpande D; Srivastava S; Bendet P; Martin KR; Cirrincione KN; Lee PS; Pasipanodya JG; Dheda K; Gumbo T
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180526
[TBL] [Abstract][Full Text] [Related]
12. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis.
Deshpande D; Srivastava S; Chapagain M; Magombedze G; Martin KR; Cirrincione KN; Lee PS; Koeuth T; Dheda K; Gumbo T
Sci Adv; 2017 Aug; 3(8):e1701102. PubMed ID: 28875168
[TBL] [Abstract][Full Text] [Related]
13. Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
Gumbo T; Pasipanodya JG; Nuermberger E; Romero K; Hanna D
Clin Infect Dis; 2015 Aug; 61 Suppl 1():S18-24. PubMed ID: 26224768
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.
Deshpande D; Pasipanodya JG; Mpagama SG; Bendet P; Srivastava S; Koeuth T; Lee PS; Bhavnani SM; Ambrose PG; Thwaites G; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S293-S302. PubMed ID: 30496461
[TBL] [Abstract][Full Text] [Related]
15. Activity of Moxifloxacin against
Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
[TBL] [Abstract][Full Text] [Related]
16. Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis.
Gonzalo X; Casali N; Broda A; Pardieu C; Drobniewski F
Int J Antimicrob Agents; 2015 Apr; 45(4):406-12. PubMed ID: 25717028
[TBL] [Abstract][Full Text] [Related]
17. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Mallikaarjun S; Chapagain ML; Sasaki T; Hariguchi N; Deshpande D; Srivastava S; Berg A; Hirota K; Inoue Y; Matsumoto M; Hafkin J; Geiter L; Wang X; Gumbo T; Liu Y
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106263
[TBL] [Abstract][Full Text] [Related]
18. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model.
Ferro BE; Srivastava S; Deshpande D; Sherman CM; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1242-8. PubMed ID: 26643339
[TBL] [Abstract][Full Text] [Related]
19. Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium tuberculosis in a Hollow-Fiber Infection Model.
Drusano GL; Myrick J; Maynard M; Nole J; Duncanson B; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Louie A
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866864
[TBL] [Abstract][Full Text] [Related]
20. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.
Deshpande D; Alffenaar JC; Köser CU; Dheda K; Chapagain ML; Simbar N; Schön T; Sturkenboom MGG; McIlleron H; Lee PS; Koeuth T; Mpagama SG; Banu S; Foongladda S; Ogarkov O; Pholwat S; Houpt ER; Heysell SK; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S308-S316. PubMed ID: 30496460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
